SI SEC InsiderScreener
‹ Screener

Savara Inc

SVRA · Pharmaceutical Preparations · 204.9M shares · +14%/yr ↑ shares · EDGAR filings ↗

Reference price $5.68 · est. market cap ~$1.2B — last insider sale, 2026-06-22 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

B71

Clinical-stage rare-respiratory biopharma whose sole asset just delivered a clean positive Phase 3 and won FDA Priority Review, materially de-risking the story despite ongoing losses.

Strengths

Risks

Notable findings

Quarterly revenue

2020-03-31 · $02020-06-30 · $02020-09-30 · $256K2020-12-31 · $1K

Last 4 quarters · from SEC filings.

Key metrics

Return on equity
-58.5%
Return on assets
-46.9%
ROIC
-41.9%
Revenue growth (QoQ)
-99.6%
Debt / equity
0.1×
Current ratio
11.8×
Free cash flow
-$101M
EBITDA
-$123M
Tangible book value
$203M
Cash & investments
$236M
Cash runway
9q

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-06-22Lowrance David LSell395K$5.68
2026-06-22Lowrance David LOption exercise75K$1.59
2026-06-22Lowrance David LTax withheld22K$5.50
2026-06-22Lowrance David LOption exercise129K$1.23
2026-06-22Lowrance David LTax withheld29K$5.50
2026-06-22Lowrance David LOption exercise57K$1.11
2026-06-22Lowrance David LTax withheld11K$5.50
2026-06-22Lowrance David LOption exercise219K$1.51
2026-06-22Lowrance David LTax withheld60K$5.50
2026-06-22Lowrance David LOption exercise12K$4.45
2026-06-22Lowrance David LTax withheld10K$5.50
2026-06-22Lowrance David LOption exercise88K$3.35
2026-06-22Lowrance David LTax withheld53K$5.50
2026-03-18Lowrance David LOption exercise131K$1.23
2026-03-18Lowrance David LOption exercise81K$1.51
2026-03-18Lowrance David LTax withheld24K$5.04
2026-03-18Lowrance David LOption exercise75K$1.59
2026-03-18Lowrance David LTax withheld24K$5.04
2026-03-18Lowrance David LTax withheld32K$5.04
2026-03-18Lowrance David LOption exercise43K$1.11
2026-03-18Lowrance David LTax withheld9.5K$5.04
2026-03-18Lowrance David LOption exercise12K$4.45
2026-03-18Lowrance David LTax withheld11K$5.04
2026-03-18Lowrance David LOption exercise25K$3.35
2026-03-18Lowrance David LTax withheld17K$5.04
2026-02-16McCracken Joseph SOption exercise1.8K$1.76
2025-12-19RAMSAY DAVID ASell20K$6.06
2025-12-16Pauls MatthewGift129K—
2025-12-16Lowrance David LGift32K—
2025-12-14Erickson AnneTax withheld63K$6.92
2025-12-14McCabe Kathleen R.Tax withheld39K$6.92
2025-12-14Lowrance David LTax withheld63K$6.92
2025-12-14Pauls MatthewTax withheld196K$6.92
2025-12-14Lutz Robert MatthewTax withheld68K$6.92
2025-12-10Pauls MatthewGift24K—
2025-12-09Hawkins Richard JGrant40K—
2025-12-09van Es-Johansson AnGrant40K—
2025-12-09Elam Nevan CGrant40K—
2025-12-09RAMSAY DAVID AGrant40K—
2025-12-09McCracken Joseph SGrant40K—
2025-12-04Wasfi YasmineTax withheld22K$6.37
2025-12-02Elam Nevan CTax withheld1.5K$5.81
2025-12-02Elam Nevan COption exercise5.9K$1.46
2025-11-14Hawkins Richard JOption exercise5.9K$1.46
2025-10-20Wasfi YasmineGrant35K—
2025-06-20Hawkins Richard JBuy48K$2.04
2025-05-29McCracken Joseph SBuy10K$2.08
2025-03-31RAMSAY DAVID ABuy150K$2.77
2025-02-13Lutz Robert MatthewTax withheld38K$2.83

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT06431776 ↗Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Autoimmune Pulmonary Alveolar Proteinosis
PHASE3Recruiting2027-06-01
NCT04544293 ↗Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Autoimmune Pulmonary Alveolar Proteinosis
PHASE3Active Not Recruiting2023-11-30
NCT03482752 ↗Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis
PHASE3Terminated2021-01-14
NCT03597347 ↗Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
PHASE2Terminated2020-10-02
NCT03181932 ↗AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
MRSA, Cystic Fibrosis
PHASE3Completed2020-07-28
NCT03421743 ↗Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
Mycobacterium Infections, Nontuberculous
PHASE2Completed2019-10-15
NCT02702180 ↗Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis
PHASE2Completed2019-04-19
NCT02468908 ↗Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
Pulmonary Alveolar Proteinosis, Bronchiectasis
PHASE1Completed2015-10-01
NCT01746095 ↗Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Cystic Fibrosis
PHASE2Completed2014-11-01
NCT01537666 ↗Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
Healthy, Cystic Fibrosis
PHASE1Completed2012-03-01
NCT06546098 ↗Molgramostim Nebulizer Solution Expanded Access Program Protocol
Autoimmune Pulmonary Alveolar Proteinosis
—Available

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Supply chain

Customers (0)

    Suppliers (5)

    Named in the 10-K; linked when we track them.

    Notable events (8-K)

    DateItems
    2026-06-08Exec/director change5.03Shareholder voteExhibitsfiling ↗
    2026-03-13Material agreementExhibitsfiling ↗
    2026-01-27Material agreementDebt obligationfiling ↗
    2026-01-09Reg FDExhibitsfiling ↗
    2025-10-30Material agreementOtherExhibitsfiling ↗
    2025-10-29Material agreementReg FDOtherExhibitsfiling ↗
    2025-09-02Reg FDExhibitsfiling ↗
    2025-06-06Shareholder votefiling ↗

    Recent filings

    FormFiledPeriodAccession
    8-K2026-06-082026-06-040001193125-26-261770 ↗
    10-Q2026-05-122026-03-310001193125-26-219371 ↗
    8-K2026-03-132026-03-100001193125-26-105099 ↗
    10-K2026-03-132025-12-310001193125-26-105076 ↗
    8-K2026-01-272026-01-260001193125-26-023378 ↗
    8-K2026-01-092026-01-090001193125-26-008301 ↗
    10-Q2025-11-122025-09-300001193125-25-277525 ↗
    8-K2025-10-302025-10-290001193125-25-258629 ↗
    8-K2025-10-292025-10-290001193125-25-256290 ↗
    8-K2025-09-022025-09-020001193125-25-193507 ↗
    10-Q2025-08-132025-06-300000950170-25-107631 ↗
    8-K2025-06-062025-06-050001193125-25-137150 ↗